Here are relevant reports on : celiac-disease-market
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Bioabsorbable Stents Market by Material (Polymer/Metal), Absorption Rate (Slow, Fast), Application (Coronary Artery Disease/CAD, Peripheral/PAD) & End User (Hospital, Cardiovascular Center) - Global Forecasts to 2022
The global bioresorbable stents market is projected to reach USD 417.2 Million by 2022, at a CAGR of 11.5%. Market growth of bioresorbable stents is attributed to the growing aging population susceptible to coronary and peripheral artery diseases, rising PCI procedures, increasing focus of companies on clinical trials of bioresorbable stents, increasing adoption of these stents by physicians and patients, and patients’ preference for minimally invasive therapies. However, factors such as the increasing product withdrawals due to severe complications of these stents may hamper market growth. The bioresorbable stents screening market is a niche market with the presence of several emerging players and few big players. Prominent players in the market include Abbott (U.S.), BIOTRONIK SE & Co. KG (Germany), REVA Medical, Inc. (U.S.), Elixir Medical Corporation (U.S.), and Kyoto Medical Planning Co., Ltd. (Japan).
- Published: August 2017
- Price: $ 4950
- TOC Available:
-
Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030
The global genomic biomarkers market, valued at US$26.78 billion in 2024, stood at US$29.00 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2024 to 2030, culminating in a forecasted valuation of US$50.31 billion by the end of the period. Genomic biomarkers are measurable features of DNA and RNA used to aid disease diagnosis, characterize disease states, and guide therapeutic decision-making.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Patient Relationship Management Software Market by Delivery (On-premise, Web & Cloud-based), Usage (PC, Laptop, Smartphone), End User (Healthcare Payers, Healthcare Providers), Application (Patient Education, Disease Management) - Global Forecasts to 2019
The global patient relationship management software market is estimated to grow at a high rate from 2014 to 2019. A number of factors such as greater emphasis on delivery of high quality patient care facilities, increasingly affordable computing infrastructure, growing integration of hospitals, data centers, clinics, and pharmacies into single service providing networks, rising awareness about personalized medicine among patients, and global burden of chronic diseases (such as cancer, orthopedic, cardiovascular and infectious diseases) are fuelling the growth of patient relationship management software market. However, reluctance to adopt advanced IT tools among healthcare providers and cost containment measures among healthcare providers has subdued IT budget of end users, which is hampering the growth of this market. Emerging markets such as Middle East, China, India, and Brazil have become attractive destinations for companies engaged in the development and marketing of patient relationship management software products. A number of factors such as growing adoption of information technology services to improve healthcare facilities and increasing market penetration of leading software companies in emerging healthcare markets are offering high growth opportunities for players active in the global patient relationship management software market.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Care Management Solutions Market by Component (Software and Services), Delivery Mode (On-Premise and Cloud-Based), Application (Disease Management, Case Management, Utilization Management), End User (Payers, Providers) & Region - Global Forecast to 2026
The global care management solutions market growth is primed to transition from $12.6 billion in 2021 to $21.6 billion by 2026, showcasing a strong CAGR of 11.4%. Key factors driving this growth include initiatives that shift risk from healthcare payers to providers, government regulations promoting patient-centric care, and increasing healthcare IT adoption.
- Published: July 2021
- Price: $ 4950
- TOC Available:
-
Cytology Brush Market by Product Type (Disposable & Reusable), Disease Type (Lung Cancer, Ovarian cancer, & Others), and End User (Hospitals, Ambulatory Surgical Centers, & Others) - Global Forecast to 2023
The global cytology brush market is expected to reach USD 83.1million by 2023 from USD 64.5 million in 2018, growing at a CAGR of 5.2%. Increasing awareness and demand for minimally invasive procedures, increasing incidence of cancer, and rising awareness about early diagnosis especially for cancer and are some of the major factors driving the growth of the global cytology brush market.
- Published: March 2026
- Price: $ 8150
- TOC Available:
-
Respiratory Antivirals Market by Disease Type (URTI, Influenza, Bronchiolitis, Pneumonia, Measles, & Others), Drug Class (Nucleoside Analogues, Neuraminidase Inhibitors, Ion Channel Blockers, Fusion Protein Inhibitors) - Global Forecast to 2019
Over the years, there has been a significant increase in the number of viral respiratory infections in humans. As a result of this, the costs to the community have increased considerably owing to the growing number of physician visits and hospitalizations. Among approximately 200 viral respiratory pathogens, the most important viral pathogens include influenza and respiratory syncytial viruses (RSVs). Antiviral drugs play an important role in the prevention and treatment of these disorders.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Neurovascular Devices Market by Disease Pathology (Cerebral Aneurysm (Embolic coils, Flow Diverters), Ischemic Stroke (Clot Retriever, Aspiration, Snare), Carotid Stenosis (Stent, Embolic Protection), Others), End User (Hospitals) - Global Forecast to 2030
The global neurovascular devices market, valued at US$4.27 billion in 2024, stood at US$4.64 billion in 2025 and is projected to advance at a resilient CAGR of 9.3% from 2024 to 2030, culminating in a forecasted valuation of US$7.22 billion by the end of the period. The market growth is primarily driven by the prevalence of neurovascular diseases, influenced by factors such as aging populations, hypertension, smoking, and sedentary lifestyles.
- Published: November 2025
- Price: $ 4950
- TOC Available:
-
Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030
The global biomarkers market, valued at US$58.07 billion in 2024, stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period. This growth is supported by the growing use of biomarkers in drug development and the increasing role of companion diagnostics in advancing precision medicine.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral)-Global Forecast to 2030
The global vaccines market, valued at US$59.52 billion in 2024, stood at US$50.46 billion in 2025 and is projected to advance at a resilient CAGR of 4.8% from 2025 to 2030, culminating in a forecasted valuation of US$63.66 billion by the end of the period.
- Published: September 2025
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
